MYM Nutraceuticals, Inc. (OTCQB: MYMMF) is engaged as a Canadian medical marijuana producer and distributor. Shares of the medical marijuana company are gaining 20%, through early trading on Monday, November 20, 2017. Over the past month, MYM Nutraceuticals, Inc. has seen average daily volume of 485,131 shares. However, volume of 476,069 shares or dollar volume of $656,975, has already exchanged hands on the day.
Shares of MYM Nutraceuticals, Inc. are climbing today, after the company announced that it has appointed Casey Houwelings and Peter Cummings as Australian greenhouse consultants. The consultants will help with advising the company on its 1.2 million square foot cannabis greenhouse project located in Northern River. Here is the full press release detailing of the appointment:
MYM Nutaceuticals, Inc. Press Release:
VANCOUVER, British Columbia, Nov. 16, 2017 /PRNewswire/ — MYM Nutraceuticals Inc. (CSE: MYM) (CSE: MYM.CN) (OTC: MYMMF) is pleased to announce that PUF VENTURES Australia (“PUFA”) has retained Mr. Casey Houwelings and Mr. Peter Cummings as greenhouse consultants for the medical cannabis Northern River Project, a 1,200,000-square foot greenhouse being constructed in north eastern New South Wales. Houwelings and Cummings will contribute to the design and construction of the most technically advanced and environmentally sustainable greenhouse to grow medical cannabis.
“We are very pleased to have both Casey Houwelings and Peter Cummings working on our medical cannabis Northern Rivers Project,” said Michael Horsfall, CEO of PUF Ventures Australia. “We have the opportunity to take an innovative approach to building one of the largest medical cannabis growing complexes in world, and Casey and Peter will lead with the advanced design of greenhouse. Their expertise will contribute to one of the most efficient and environmentally sustainable design on the planet, as we strive to have the highest quality and lowest cost cannabis that is grown under the sun. We believe that natural sunlight will be a significant advantage with the advanced growing systems under consideration, and will allow us to maximize the climate of the beautiful Richmond Valley Shire in the Northern Valley Region of Australia.”
Mr. Houwelings is Chairman of one of the most technically-advanced and environmentally-friendly greenhouse operations in the world – the Houweling Group of companies. Presently, he oversees the successful operation of three large-scale greenhouses in California, Utah and British Columbia. Over his career, he has successfully designed intellectual property for the greenhouse industry which has lowered costs, improve yields, and reached the highest standard of product. Mr. Houwelings will incorporate commercial techniques and systems gained for his greenhouse experience in Canada and the USA and apply them to the medical cannabis Northern Rivers Project.
Mr. Cummings is recognized as a leader in modelling greenhouse projects around the world. He was a Canadian Chartered Accountant until 2010 and the CFO of the Houweling Group of companies until 2012. Mr. Cummings has worked with Mr. Houwelings for over 20 years. Both are currently employed with several cannabis companies in Canada and will work exclusively PUFA in Australia.
Northern Rivers Project
The Northern Rivers Project is a joint venture between PUF Ventures, PUF Ventures Australia, and MYM Nutraceuticals, to build a 1.2 million square foot greenhouse operation on a 27-hectare parcel of land near the town of Casino in northern New South Wales, Australia. When complete, the greenhouse will be one of the most technically advanced and environmentally sustainable medical cannabis operations in the world and include large-scale greenhouse, manufacturing, processing and office facilities for the cultivation, production and manufacture of medical cannabis and associated products in Australia. The first phase of the project will cover approximately 300,000 square feet, which will be the largest medical cannabis greenhouse in Australia.
MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. MYM has two production projects in Quebec that when completed will have over 1.5 million sqft of production space. MYM is also a partner in a 1.2 million sqft production project (Northern Rivers Project) in New South Wales, Australia. Australia is an exciting new market that recently legalized cannabis and MYM is a pioneering leader there. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).
This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.
This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.